Literature DB >> 18729016

5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia.

Christopher N Johnson1, Mahmood Ahmed, Neil D Miller.   

Abstract

Several serious neurological and psychiatric disorders are associated with cognitive impairment. Thus, drugs targeting the cognitive symptoms of these diseases would be expected to provide significant benefits to these patient populations. A growing body of preclinical evidence has supported the use of serotonin 5-HT6 receptor antagonism as a promising mechanism for treating cognitive dysfunction. Following the discovery of a new generation of 5-HT6 receptor ligands with improved physicochemical properties, leading to superior brain penetration, additional support for the 5-HT6 hypothesis has been provided by clinical trial data for three molecules in drug development.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18729016

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN： 1367-6733


  9 in total

Review 1.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

2.  Distribution of serotonin receptor of type 6 (5-HT₆) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study.

Authors:  Donatella Marazziti; Stefano Baroni; Andrea Pirone; Gino Giannaccini; Laura Betti; Lara Schmid; Elena Vatteroni; Lionella Palego; Franco Borsini; Fabio Bordi; Ilaria Piano; Claudia Gargini; Maura Castagna; Mario Catena-Dell'osso; Antonio Lucacchini
Journal:  Neurochem Res       Date:  2012-01-26       Impact factor: 3.996

3.  The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats.

Authors:  Eric G Mohler; Phillip M Baker; Kimberly S Gannon; Simon S Jones; Sharon Shacham; John A Sweeney; Michael E Ragozzino
Journal:  Psychopharmacology (Berl)       Date:  2011-10-12       Impact factor: 4.530

4.  N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties.

Authors:  Paweł Zajdel; Krzysztof Marciniec; Grzegorz Satała; Vittorio Canale; Tomasz Kos; Anna Partyka; Magdalena Jastrzębska-Więsek; Anna Wesołowska; Agnieszka Basińska-Ziobroń; Jacek Wójcikowski; Władysława A Daniel; Andrzej J Bojarski; Piotr Popik
Journal:  ACS Med Chem Lett       Date:  2016-04-07       Impact factor: 4.345

5.  Over-expression of 5-HT6 Receptor and Activated Jab-1/p-c-Jun Play Important Roles in Pilocarpine-Induced Seizures and Learning-Memory Impairment.

Authors:  Changyun Liu; Yuxing Wen; Huapin Huang; Wanhui Lin; Mingzhu Huang; Rong Lin; Ying Ma
Journal:  J Mol Neurosci       Date:  2019-01-29       Impact factor: 3.444

Review 6.  The role of serotonin in memory: interactions with neurotransmitters and downstream signaling.

Authors:  Mohammad Seyedabadi; Gohar Fakhfouri; Vahid Ramezani; Shahram Ejtemaei Mehr; Reza Rahimian
Journal:  Exp Brain Res       Date:  2014-01-16       Impact factor: 1.972

7.  5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia.

Authors:  Julie Meffre; Séverine Chaumont-Dubel; Clotilde Mannoury la Cour; Florence Loiseau; David J G Watson; Anne Dekeyne; Martial Séveno; Jean-Michel Rivet; Florence Gaven; Paul Déléris; Denis Hervé; Kevin C F Fone; Joël Bockaert; Mark J Millan; Philippe Marin
Journal:  EMBO Mol Med       Date:  2012-10       Impact factor: 12.137

Review 8.  AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

Authors:  Alexandre V Ivachtchenko; Yan Lavrovsky; Ilya Okun
Journal:  J Alzheimers Dis       Date:  2016-05-25       Impact factor: 4.472

Review 9.  The Role of Serotonin Neurotransmission in Gastrointestinal Tract and Pharmacotherapy.

Authors:  Tomasz Guzel; Dagmara Mirowska-Guzel
Journal:  Molecules       Date:  2022-03-03       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.